Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07109778

Copper to Zinc Ratio in End Stage Renal Disease Patients Outcome

The goal of this observational clinical trial is to Study the impact of copper to zinc ratio on the outcome of ESRD patients

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Nephrology and urology hospital, Minia unersity hospital, Faculty of medicine, Minia university

Minya, Egypt

Location contact

Shima Hassan Hamdy, MD of Internal medicine

CONTACT

About this study

End-stage renal disease (ESRD) carries high morbidity and mortality due to cardiovascular complications, highlighting the need for ongoing research. Trace elements as copper (Cu), and zinc (Zn), are essential for physiological functions, enzyme activity, metabolism, and immune defense. In ESRD patients, Cu and Zn imbalances, with a higher Cu/Zn ratio are linked to greater cardiovascular problems. The relationship between the Cu/Zn ratio and clinical outcomes in ESRD needs more exploration

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ESRD patients including those on maintenance HD

Exclusion criteria

  • Acute kidney injury or rapidly progressive glomerulonephritis, acute infections or active inflammatory conditions as sepsis and autoimmune diseases, liver cirrhosis (Child-Pugh Class B or C), gastrointestinal disorders as inflammatory bowel disease, malabsorption, history of organ transplantation excluding kidney transplantation who may be included in a separate analysis if sufficient numbers are recruited, receiving total parenteral nutrition, Cu or Zn metabolism disorders as Wilson's disease, vitamin complex supplementation or antioxidants within the past 6 months, recent hospitalization within the past 3 months, recent surgery within 3 months, recent blood transfusion < 3 months, Pregnancy or lactation, Malignancy.

Treatment and study plan

Primary outcomes

  1. To determine whether an elevated serum Cu/Zn ratio is associated with an increased risk of cardiac complications in chronic hemodialysis patients.

    Time frame: 6-8 months

    measuring serum Cu/Zn ratio and determining if it is associated with an increased risk of cardiac complications in chronic hemodialysis patients.

Study contacts

Contact information is provided by the study sponsor or research team.

Kerolles Adel Estawrow Saleh, MBChB

CONTACT

[email protected]

01227657867

Sponsors and collaborators

Lead sponsor

Minia University

Other

Registry information

Official study title

Impact of Copper to Zinc Ratio on Outcome of End Stage Renal Disease Patients

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Aug 7, 2025
Registry last updated
Aug 7, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.